Reports of symptoms returning in patients several days after completing the five-day regimen of Paxlovid
COVID-19 Drug Paxlovid Might Also Fight Long COVID
Series of case reports shows some success with Paxlovid in treating patients with long COVID
Dapagliflozin Well Tolerated in COVID-19 Patients, Regardless of eGFR
Effects of dapagliflozin on primary and secondary outcomes consistent for those with eGFR <60 and ≥60 mL/min per 1.73 m2
FDA Approves First COVID-19 Treatment for Use in Children
Veklury had already been fully approved to treat people 12 years and older
White House Moves to Make COVID-19 Antiviral Pills More Widely Available
Many Americans have said they cannot find a doctor to prescribe Paxlovid or a pharmacy that has it
Living Guideline Updated for Drug Treatment of COVID-19
Tenth version recommends nirmatrelvir/ritonavir in patients with confirmed COVID-19 who have highest risk for hospitalization
Single Dose of AZD7442 Effectively Prevents COVID-19
Relative risk reduction of 82.8 percent seen in symptomatic COVID-19 at extended follow-up of median of six months
Drug Interaction Checkers Could Have Caught Adverse Events
More than three-quarters of COVID-19-associated drug-drug interactions could have been identified
Single Dose of AZD7442 Prevents Symptomatic or Severe COVID-19
Relative risk reduction of 82.8 percent seen in symptomatic COVID-19 at extended follow-up of median of six months
Subcutaneous mAb May Benefit High-Risk Outpatients With COVID-19
SC casirivimab and imdevimab linked to reduced 28-day hospitalization or death for high-risk outpatients with mild to moderate COVID-19